Since its discovery by Kohler and Milstein in 1975, hybridoma technology has found a wide use in almost every field of biology and medicine. A general and simple approach for developing monoclonal antibodies is to use splenocytes from immunized mice. In the present study, 10 fusion experiments were carried out to analyze the hybridization efficiencies of mouse myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow and we found a higher yield of antigen specific antibody producing hybridoma lines when the lymph nodes were used. 329 
INTRODUCTION K
OHLER AND MILSTEIN'S revolutionary work-hybridoma technology-made it possible to fuse mouse myeloma cells with B lymphocytes from immunized mice, thus resulting in antibody-producing somatic cell hybrids. (1) Since then, hybridoma technology has become widely adopted, and monoclonal antibodies (MAbs) have provided the solution to many biological problems. The most interesting and unique characteristics of a MAb is its specificity, not just for the immunizing protein but for a particular epitope region on it. In the past two decades, MAbs specific for numerous antigens (e.g., bacteria, viruses, parasites, tumor antigens, receptors, hormones, enzymes) have been generated, and MAbs have found widespread use in many areas of medical research, diagnostics, and therapeutics. (2) (3) (4) Although MAbs are powerful scientific tools and diagnostic reagents, there are still some unsolved practical problems. These technical problems include obtaining mAbs with high affinity and adequate specificity to very weak immunogens and antigens that are available in only very small amounts.
In the traditional hybridoma technology, mice are immunized with desired antigen and once the animals are making a good antibody response, MAbs are generated by fusing the mouse splenocytes with a B cell myeloma from the same strain. In the investigation reported below, we used lymphocytes derived from spleen, lymph nodes, and bone marrow to enhance the chance of obtaining MAbs to weak or rare antigens.
MATERIALS AND METHODS

Antigens
Hepatitis B surface antigens (HBsAg; Chemicon AG-850, AG-852, Temecula, CA), Verticillium dahliae, vascular endothelial growth factor-bovine serum albumin mixture (VEGF-BSA; National Cancer Institute, Biological Resources Branch, Bethesda, MD), and anti-HBV IgG antibody were used as the immunogen. All antigens were emulsified with equal volume of Freund's complete and incomplete mineral oil adjuvant, respectively, and immunizations were performed intraperitonally. Booster immunizations were done in phosphate buffered saline (PBS) by systemic routes.
Fusion
Fusion was carried out by some modifications of classical fusion protocols. (5) Briefly, lymphocytes from spleen, lymph nodes (bronchial, axillar, inguinal, popliteal, and intraperitonal), and bone marrow were fused with F0 (ATCC CRL 1646) mouse myeloma cells, and PEG 4000 was used as the fusing agent. Hybrid cells were selected by incubating cells in HAT medium, and positive clones were selected with ELISA. (6) Cloning and subcloning were performed as described. (7) ELISA Antigen-specific immune activity was determined by ELISA. Microtiter ELISA wells were coated with HBsAg (400 ng/mL), VEGF-BSA (400 ng/mL), Goat anti-HBV polyclonal antibody (1 mg/mL), and Verticillium dahliae (surface antigens, 1 mg/mL) in PBS at 4°C by overnight incubation, and unbound antigens were removed by washing with PBS 1 0.05% Tween-20. Free sites were blocked with 200 mL of 1% BSA or powdered milk for 1 h at 37°C and wells thoroughly washed. The diluted mouse serum or hybrid cell supernatant was added to each well and incubated for 1 h at 37°C. After washing, alkaline phosphatase conjugated goat antimouse IgG/IgM and polyvalent antibody (Sigma, St. Louis, MO, diluted as 1/4000, 1/1000 and 1/1000, respectively) were added. After 1 h of incubation at 37°C, the plates were washed, and PNPP (para nitrophenyl phosphate) at 1 mg/mL in substrate buffer (0.1 M glycine, pH 10.4, 1 mM ZnCl 2 , and 1 mM MgCl 2 ) was added. The absorbance at 405 nm was read on a BioTec (Winooski, VT) EIA reader.
RESULTS AND DISCUSSION
Production of MAbs involves labor-and time-intensive procedures, lengthening their production time and ultimately their cost. Most laboratories engaged in the production of MAbs currently use lymphocytes from spleen. In the present study, a total of 10 fusions were carried out using lymphocytes from spleen and lymph nodes separately after immunizing animals with different antigens. Table 1 shows the number of total hybrid cells and antigen specific antibody producing hybrid cells from spleen and lymph nodes, respectively. When we compared the yield, the number of total hybrid cells seem higher in fusions performed using splenocytes. On the contrary, the number of hybridomas producing antibody of interest using lymph nodes was about two times higher than that of hybridomas with the conventional method using mouse spleen cells-four versus 10.
The efficient use of lymph nodes for generating monoclonal antibodies with high specificity and affinity to antigens was also shown by other investigators. (8) Bynum and co-workers reported making high-affinity monoclonal antibodies by somatic fusion of lymphocytes isolated from peripheral lymph nodes.
BAŞALP AND YÜCEL 330
Sado et al. also used iliac lymph nodes for cell fusion and have shown that the production frequency of target hybridomas was about 10 times higher than that of a conventional spleen method. (10) Kimura et al. showed that fusion of popliteal lymph node lymphocytes produced hybridomas secreting antibodies to the peptide moiety of erythrocyte membrane protein. On the other hand, splenic lymphocyte fusion produced hybridomas secreting antibodies to the carbohydrate moiety of the same antigen. (11) Our data shown here is consistent with the previously reported results and reveal the generation of MAbs to antigens with higher specificity using lymph nodes. It is well established that, in mammals, lymphocytes circulate between bone marrow, spleen and lymph nodes and these organs are the major sites of antibody production in secondary immune response and thus, can be used as a source of activated B lymphocytes. Lymph nodes are small noduler aggregates of lymphoid tissue situated along lymphatic channels throughout the body and form part of a network that filters antigens from the interstitial tissue fluid. IFN) and represents a special environment that supports and facilitates antibody production. Dilosa et al. have shown that germinal center B cells migrate to the bone marrow and produce large quantities of specific antibody associated with secondary immune response. (13) In four seperate fusions, bone marrow was isolated from immune animals, and lymphocytes were fused with mouse myeloma cells. Although primary hybridomas could be established from fusions with bone marrow-derived cells, only one out of 932 hybrid cells was production registered ( Table 2) .
The results of this study indicate that the use of spleen, lymph nodes, and bone marrow in the same fusion after immunizing mice, especially with the rare or less immunodominant antigens, maximizes the chance of generating MAbs with the fewest attempts. This approach is a time-and labor-saving technique for making monoclonal antibodies.
